Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $56.0 million.

  • Zevra Therapeutics' Shares Outstanding (Weighted Average) rose 1703.28% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 1703.28%. This contributed to the annual value of $46.3 million for FY2024, which is 3045.99% up from last year.
  • Per Zevra Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $56.0 million for Q3 2025, which was up 1703.28% from $54.8 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $56.0 million for Q3 2025, and its period low was $19.1 million during Q1 2021.
  • For the 5-year period, Zevra Therapeutics' Shares Outstanding (Weighted Average) averaged around $38.6 million, with its median value being $34.7 million (2023).
  • Examining YoY changes over the last 5 years, Zevra Therapeutics' Shares Outstanding (Weighted Average) showed a top increase of 64771.5% in 2021 and a maximum decrease of 6017.3% in 2021.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Shares Outstanding (Weighted Average) stood at $29.8 million in 2021, then rose by 15.87% to $34.5 million in 2022, then rose by 2.79% to $35.5 million in 2023, then surged by 30.46% to $46.3 million in 2024, then rose by 20.97% to $56.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $56.0 million in Q3 2025, compared to $54.8 million in Q2 2025 and $54.1 million in Q1 2025.